EP2861216B1 - Orale pharmazeutische formulierung mit bcs-klasse iii-molekülen - Google Patents

Orale pharmazeutische formulierung mit bcs-klasse iii-molekülen Download PDF

Info

Publication number
EP2861216B1
EP2861216B1 EP13729029.2A EP13729029A EP2861216B1 EP 2861216 B1 EP2861216 B1 EP 2861216B1 EP 13729029 A EP13729029 A EP 13729029A EP 2861216 B1 EP2861216 B1 EP 2861216B1
Authority
EP
European Patent Office
Prior art keywords
labrasol
water
microemulsion
baclofen
formulation according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP13729029.2A
Other languages
English (en)
French (fr)
Other versions
EP2861216A1 (de
Inventor
Caroline AILHAS
Catherine Herry
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ethypharm SAS
Original Assignee
Ethypharm SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ethypharm SAS filed Critical Ethypharm SAS
Publication of EP2861216A1 publication Critical patent/EP2861216A1/de
Application granted granted Critical
Publication of EP2861216B1 publication Critical patent/EP2861216B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Definitions

  • the invention relates to an oral pharmaceutical formulation of BCS class III molecule, baclofen, having improved bioavailability and permeability.
  • the oral route is the route considered first when shaping a new pharmaceutical entity by the adherence to the treatment it induces.
  • this pathway is abandoned for many molecules in development because of their low oral bioavailability. This may be due to various factors arising from the properties of the molecule itself or from the physiology of the gastrointestinal tract (Fasinu, et al., 2011).
  • Various approaches have been explored over the last decade to improve the oral bioavailability of these molecules including physical or chemical means.
  • BCS molecules Biopharmaceutics Classification System
  • FDA, EMEA and WHO Food and Waterhouse
  • a molecule is considered soluble if the maximum dose of an immediate release form is soluble in 250 ml or less of an aqueous medium having a pH of between 1.2 and 6.8 and is considered permeable if absorbed through the intestinal membrane is greater than or equal to 90%.
  • a BCS molecule in class III is highly soluble and weakly permeable. This last characteristic is the factor limiting the oral bioavailability and can lead to the abandonment of the development of oral formulation of molecules having however a strong therapeutic potential.
  • baclofen is known to have good oral bioavailability.
  • its low log P indicates a certain hydrophilicity and therefore a low permeability. This observation is explained by the presence of specific transporters in the small intestine allowing the passage of the molecule. This is all the more important in the jejunum.
  • a weak passage in the colon supposes the presence of another mechanism of passage through the intestinal barrier (Merino, et al., 1989). This area of the digestive system does not contain transporters, but since the molecule is hydrophilic and small, a weak pass through the tight junctions is possible.
  • the solution used in the clinic is then the taking of small doses at short time intervals which can quickly become binding for the patient.
  • baclofen ester prodrugs An increase in the lipophilicity of baclofen and hence in its transcellular permeability has been observed through the production of baclofen ester prodrugs (Leisen, et al., 2003). Due to these properties, a greater concentration of prodrug is found in the target tissue, the brain, thanks to an easier passage of the blood-brain barrier. However, greater affinity for the P-gp efflux pump as well as partial hydrolysis of the prodrug to baclofen is noted, which ultimately leads to a lower baclofen site-of-action level after administration of the prodrug compared with administration of baclofen alone.
  • a window of baclofen absorption is evidenced in the small intestine due to the presence of transporters (Merino, et al., 1989). In order to increase the bioavailability, this absorption window could thus be exploited by galenic techniques allowing the retention of the oral form at the level of the window or upstream (Davis, 2005). Indeed, a longer residence time at the site of absorption should theoretically allow a greater passage of molecules across the intestinal barrier if they are not likely to undergo pre-systemic degradation before absorption.
  • bioadhesive forms to the intestinal mucus through the use of cationic polymers such as chitosan or gastroretentive forms allowing the swelling and flotation of the form at the level of the stomach have appeared in recent years in pharmaceutical development but their effectiveness is highly dependent on intra- and inter-individual variability.
  • the tight junctions having a role of barrier and therefore defense of the body, it is important that the promoters acting on their opening have a reversible action and do not induce toxicity.
  • the US patent application US2010 / 029771 discloses a liquid pharmaceutical formulation that can be incorporated into a capsule for the treatment of gastroparesis and non-ulcer dyspepsia with gamma-aminobutyric acid-B (GABAB) receptor agonists, such as baclofen for example.
  • GABAB gamma-aminobutyric acid-B
  • the object of the invention relates to an oral pharmaceutical formulation based on a microemulsion between an aqueous phase comprising at least one active ingredient BCS (Biopharmaceutics Classification System) class III, said active ingredient being baclofen, and a oily phase comprising an oily excipient self-emulsifiable in contact with water.
  • BCS Biopharmaceutics Classification System
  • the formulation according to the invention has the advantages of improved intestinal membrane permeability and nontoxicity.
  • microemulsion means an emulsion whose droplet size is less than 200 microns.
  • a self-emulsifiable oily excipient in contact with water means an excipient which will spontaneously form an oil-in-water emulsion with an aqueous phase, ie droplets of the aqueous phase surrounded by a lipid layer comprising excipient.
  • in vivo techniques in the rat or ex-vivo can be performed (Koga, et al., 2002) ( Lin, et al., 2007) (Constantinides, et al., 1996).
  • In vitro techniques are also used on the rat intestinal membrane or on cell cultures.
  • evaluation on the Caco-2 cell line is very often used (Sha, et al., 2005).
  • Caco-2 cells are derived from human cancer cell culture capable of differentiation in the presence of a suitable culture medium (Pontier, 1997-1998). Their properties are a function of the number of subcultures to which they are subjected. The cell clone obtained at passage 198 has characteristics close to the enterocytes. Caco-2 cells are slightly smaller in size than healthy enterocytes but have a monolayer comparable to that of the small intestine epithelium. The brush border is differentiated and developed and very narrow junctions of 10 to 50 ⁇ are present (narrower than those of the small intestine). From a biochemical point of view, Caco-2 cells also express enterocyte enzymes. Moreover, many transporters are present but their expression is lower than the levels found in vivo and the efflux pump P-gp is overexpressed which can underestimate an absorption compared to the in vivo.
  • the MTT test is an indicator of mitochondrial integrity and activity and is comparable to a measure of cell viability (Sigentec). This test is based on the activity of a mitochondrial enzyme, succinate dehydrogenase.
  • the substrate MTT 3- [4,5-dimethylthiazol-2-yl] -2,5-diphenyltetrazolium bromide
  • the tetrazolium salts of the substrate are converted into insoluble crystals of formazan by the activity of succinate dehydrogenase.
  • the amount of formazan salt is then assayed spectrophotometrically and is compared to a negative control having a cell viability of 100% (Buyukozturk, et al., 2010).
  • transepithelial electrical resistance (or TEER) (in ohms / cm 2 ) makes it possible to evaluate cellular integrity (Pontier, 1997-1998). This makes it possible to evaluate the toxicity of the tested product. The measurement is made before and after the test and the loss of resistance must not exceed 30% to conclude that it is non-toxic (Oroxcell, 2011).
  • Lucifer yellow (LY) is a marker for paracellular passage (Buyukozturk, et al., 2010). Its dosage in the recipient compartment during the permeability test makes it possible to observe an opening of the tight junctions. The test can also be done after the test to assess cell integrity (Nollevaux, et al., 2006). The apparent permeability of luciferyellow under normal conditions is 3.10 7 cm / s (Oroxcell, 2011).
  • the ratio BCS active principle of class III / self-emulsifiable oily excipient in contact with water by weight is between 1/10 to 1/100, particularly preferably between 1/40 and 1/80.
  • the oily phase represents from 1 to 50% of the microemulsion, more preferably from 2 to 30%, particularly preferably from 5 to 25%, or even from 15 to 20%.
  • the aqueous phase of the microemulsion of the formulation of the invention is a solution in which the active ingredient BCS class III is solubilized.
  • the microemulsion of the formulation of the invention is an oil-in-water microemulsion consisting of an aqueous phase comprising at least one active ingredient BCS (Biopharmaceutics Classification System) class III which is baclofen and an oily self-emulsifiable vehicle in contact with water.
  • BCS Biopharmaceutics Classification System
  • the active principle of the formulation according to the invention is baclofen.
  • it is solubilized in the aqueous phase, preferably in 0.01M fumaric acid.
  • a self-emulsifiable oily excipient in contact with the appropriate water has an HLB (Hydrophilic-Lypophilic Balance) greater than 12, particularly preferably 13 or 14, for example it is Labrasol® (Gattefossé ) composed of caprylocaproylmacrogolglycerides or semi-solid Gelucire® 50/13 composed of Lauroylmacrogolglycerides (Gattefossé).
  • HLB Hydrophilic-Lypophilic Balance
  • Miglyol® (Sasol) and Captex® ( Abitec) are triglycerides of capric (C10) and caprylic (C8) acid.
  • Capmul®MCM (Abitec) is composed of mono- and di-glycerides of capric and caprylic acid (Table 2).
  • Labrasol® (Gattefossé) is composed of caprylocaproylmacrogolglycerides, which consists of a mixture of mono-, bi- and triglycerides as well as esterified fatty acids of propylene glycol (Gattefossé). Its characteristics (Table 2), and in particular its miscibility in water, are particularly interesting from a formulation point of view.
  • Gelucire® 50/13 (Table 2) is a semi-solid excipient having a high HLB of 13 compounds of Lauroylmacrogolglycerides (Gattefossé). Palmitic acid and stearic acid are the fatty acids that make up Gelucire®.
  • the self-emulsifiable oily excipient of the microemulsion of the formulation of the invention is Labrasol®, a mixture of caprylocaproylmacrogolglycerides which consists of a mixture of mono-, bi- and triglycerides of acids. esterified fatty acids of propylene glycol -8, with a proportion of 50 to 80% of caprylic acid and 20 to 50% of capric acid.
  • Another object of the invention relates to a formulation according to the invention for its use in the treatment of alcohol dependence or the maintenance of weaning alcoholics.
  • Another subject of the invention relates to the use of a microemulsion between an aqueous phase comprising at least one class III active ingredient BCS (Biopharmaceutics Classification System) which is baclofen and an oily phase comprising an oily excipient which is self-contained. emulsifiable in contact with water for the manufacture of a medicament for the treatment of alcohol dependence or maintenance of alcohol withdrawal.
  • BCS Biopharmaceutics Classification System
  • the pharmaceutical formulation of the invention may be any oral pharmaceutical dosage form known to those skilled in the art, both liquid and solid.
  • Suitable liquid formulations are any liquid pharmaceutical formulation in which the microemulsion between an aqueous phase comprising at least one class III active biopharmaceutics classification system (BCS) and an oily phase comprising a self-emulsifiable oily excipient in contact with water. stable.
  • BCS active biopharmaceutics classification system
  • Microemulsions once formed, can be directly introduced into capsules for oral administration, flexible or rigid, for example gelatin.
  • the aqueous phase of an emulsion can also be spray dried in a fluidized air bed to form a "dry emulsion".
  • adsorption on a solid support such as microcrystalline cellulose or silica
  • a granulating mixer allows the adsorption of a large amount of liquid excipient while maintaining good flow properties.
  • the support impregnated with the emulsion can be used to formulate tablets with compressional excipients.
  • the formulation according to the invention may comprise any additional conventional formulation excipient.
  • the formulation according to the invention comprises from 10 to 80 mg of active ingredient per unit dose, preferably from 20 to 60.
  • Labrasol® and Gélucire® 50/13 come from Gattefossé®, Miglyol® 810 from Sasol® Germany GmBH and Capmul® MCM and Captex® 355 from Abitec®.
  • Excipients used in the various tests are: fumaric acid (Merck), Avicel® PH102 (microcrystalline cellulose, FMC Biopolymer), Neusilin® (magnesium aluminometasilicate, FugiChemicalIndustry), HPMC 603 (hydroxypropyl methylcellulose, Shin Etsu), Tween® 80 (polysorbate 80, Sigma).
  • solubilities of the active ingredient in the excipients are determined by a visual method, by introducing exactly weighed quantities of baclofen into the selected excipent after stirring for 24 hours. At first, the solubilities at room temperature of baclofen in Labrasol®, Miglyol® 810 and Captex® 355 are evaluated. The solubility of baclofen in Gelucire® 50/13 is determined after melting of the excipient at a temperature above 50 ° C and then placed in a thermostatically controlled oven at 60 ° C.
  • baclofen in aqueous medium, it is evaluated in an acidified solution of fumaric acid 0.01 M. Fumaric acid does not induce stability problem with baclofen according to an internal report of binary compatibilities.
  • Miglyol® 810, Capmul® MCM and Captex® 355 are water-immiscible excipients.
  • Baclofen being a hydrophilic molecule, it is chosen to formulate microemulsions from these excipients by the use of pseudo-ternary diagrams. That is to say having a surfactant-cosurfactant ratio of fixed composition but by varying the proportion of this mixture with the oily and aqueous phases.
  • the objective is to formulate an oil-in-water (O / W) microemulsion and a water-in-oil (W / O) microemulsion.
  • the aqueous phase consisting of purified water, is added last with stirring. Microemulsions are formed instantly. Then, once the compositions of the mixtures have been selected, tests are carried out with an aqueous solution of fumaric acid 0.01 M to 6 mg / ml of baclofen.
  • Labrasol® and Gelucire® 50/13 are self-emulsifying excipients in the presence of water.
  • Various water / Labrasol® or water / Gélucire® 50/13 ratios are tested.
  • the water / Gelucire® 50/13 mixtures are made at a temperature above 50 ° C while the water / Labrasol® mixtures are made at room temperature.
  • the viscosity of the emulsions is determined using a Brookfield DV-II + rotary viscometer and the SC4-18 mobile using a cylindrical Couette geometry.
  • the particle size of the emulsions is measured by quasi-elastic light scattering on a Coulter® N4 plus particle size analyzer. The measurements are made at a 90 ° angle directly on the emulsions, taking into account the characteristics of the dispersing medium (viscosity, refractive index) and then after dilution in water. The dilution factor is dependent on the intensity measured at 90 ° which must be between 5.10 4 and 1.10 6 counts / sec for the validity of the measurement. Each measurement is done in triplicate.
  • Caco-2 cells were cultured and differentiated for 21 to 30 days. They have undergone a number of subculturing of less than 110.
  • the culture medium is a DMEM medium (Dulbecco'sModifiedEagle Medium) supplemented with 10% inactivated fetal calf serum, 1% non-essential amino acids and antibiotics.
  • the Caco-2 cells allowed the evaluation of the potential of eight formulas, presented in Tables 5a, 5b, 5c and 5d, in improving the apparent permeability of baclofen.
  • the dilutions made are at the choice of the subcontractor according to the concentration of baclofen measurable by the assay technique and as a function of the lowest non-toxic concentration given by preliminary toxicity studies.
  • the compositions of the apical and basolateral media are given in Table 3 below.
  • the result must be between 75 and 125%.
  • permeability of a reference compound is also measured as a positive control. It is metoprolol at 20 ⁇ M, a molecule borrowing a transcellular active transport. Baclofen alone is also used as a negative control.
  • transepithelial resistance Before each test, a measurement of transepithelial resistance is performed. This must be greater than 1500 ⁇ . A second measurement is performed after the test. If the loss of resistance is greater than 30%, it is concluded that the monolayer has deteriorated.
  • Labrasol® is the excipient selected for the formulation of a solid form.
  • the adsorption / granulation tests are carried out in a Diosna PVAC 10 mixer / granulator. A 2L tank and a 0.8 mm spray nozzle are used.
  • Granulation tests are carried out on microcrystalline cellulose (Avicel® PH102) according to Table 6.
  • the rotational speed of the background powder is 200 rpm and that of the roter 1500 rpm.
  • the spray rate is 30 g / min.
  • a drying time of one hour at 50 ° C under Vacuum is necessary to obtain a grain containing residual moisture of less than 5% (ThermobalanceMettler). The grain is then screened on 0.5 mm mesh.
  • the particle size is measured by Malvern® laser granulometer and the data is processed using the Mastersizer 2000 software.
  • the grain capacity for compressibility and flow is evaluated by measuring the apparent volume under compaction (STAV 2003 volumetric meter) and Calculation of the Carr index as well as measurement of the flow time on 100 g of powder through a standardized funnel. These tests are carried out according to the European Pharmacopoeia in force ( European Pharmacopoeia 7th edition, 2012 ).
  • Simple adsorption tests are also carried out in a mixer by introducing Labrasol® into Avicel® PH102 or Neusilin® (Magnesiumaluminometasilicate) with stirring of the blades respectively at 150 and 300 rpm.
  • the flow rate is 20 g / min and the tests are carried out hot at 40 ° C under vacuum in order to fluidize the oily excipient Labrasol.
  • the following adsorbents are also tested: Fujicalin®, Hubersorb®, 600 and Syloid®244FP.
  • solubilities indicated in Table 7 below are determined according to the visual observation of particles in the media. ⁇ b> ⁇ i> Table 7: Baclofen solubility results in various media ⁇ / i> ⁇ /b> Product Temperature Solubilities of baclofen Miglyol®810 ambient ⁇ 0.1 mg / ml Captex® 355 ambient ⁇ 0.1 mg / ml Labrasol ambient 0.2-0.4 mg / ml Gelucire® 50/13 60 ° C 0.5-1 mg / ml Aqueous medium 0.01M fumaric acid ambient 6-7 mg / ml
  • compositions 1, 2 and 3 allow obtaining clear media and the composition 10 produces a milky medium.
  • the compositions 8 and 9 are opaque and a phase shift is obtained after 24 hours.
  • compositions based on Captex® 355 and Capmul® MCM provide clear microemulsions.
  • Microemulsions made with active principle do not have a visual difference compared to those without active ingredient.
  • Labrasol® is miscible in all proportions in water. However, a clear and homogeneous mixture appears for Labrasol concentrations greater than 1% in water. For concentrations below 1%, the medium is cloudy and the particles visible to the naked eye sediment.
  • Gelucire® is also miscible with water but only water / Gelucire® mixtures at concentrations below 5% remain in liquid form at room temperature.
  • compositions are selected for cell permeability tests and are here characterized.
  • the viscosities of the microemulsions are given in Table 8 below.
  • the torque value provides an indication of the reliability of the measurement.
  • Table 8 viscosity of microemulsions at room temperature ⁇ / i> ⁇ /b> Sample Rotation speed of the mobile (rpm) Torque Value (%) Measured viscosity (cP) Miglyol® microemulsion / Labrasol® 6 85 423 Capmul® / Captex® microemulsion 30 60 59
  • the viscosities of the binary mixtures are close to that of water.
  • the granulometries are measured 14 days after the preparation of the systems, before and after dilution for the microemulsions as well as for the water / Labrasol® binary mixtures. The results are shown in Tables 9 and 10.
  • the dilution causes destabilization and the appearance of an opaque medium whose intensity at 90 ° is too high for the measurement of particle sizes. Dilution is therefore necessary to have an intensity within the range recommended by the manufacturer of the particle size analyzer.
  • the characteristics and in particular the viscosity of the undiluted Miglyol® / Labrasol® emulsion do not allow measurements on the Coulter granulometer.
  • the dilution achieved is identical to that of the Caco-2 cell assays.
  • Granulometric measurements shown in Table 9, are also made and are compared to those obtained at 14 days. No phase shift appears for microemulsions placed at room temperature after 45 days.
  • the apparent permeability of metoprolol is very high, being greater than 6.10 -6 cm / s, as expected. This is a witness of the transcellular passage and its lack of effect on the opening of the tight junctions demonstrated above validates the experimental conditions.
  • the most promising formulas for increasing the membrane passage of baclofen are the formulas based on Labrasol®, more particularly those at 10% and 25% which respectively allow increases of 20 and 28 times the apparent permeability of non-baclofen. formula.
  • the recovery rates calculated during the tests are around 100% which confirms the absence of degradation of the product during the test. No loss is observed.
  • a grain containing 33% Labrasol® is obtained. It is yellow in color and greasy to the touch.
  • the particle size results are indicated in the figure 9 .
  • Adsorption tests on microcrystalline cellulose at the same concentration as that obtained in granulation provide a yellow, oily powder of "wet sand" appearance and forming clusters.
  • the objective of this step is to select an excipient for future compression tests, the charged excipients are characterized by flow by measuring the flow rate and the Carr (Ic) index (Table 12).
  • the adsorbed powders without flow (Hubersorb® 600, Avicel® PH102, Neusilin® US2, Syloid® 244FP) are not retained.
  • baclofen is a hydrophilic PA, as indicated by its log P of -0.96 (Benet, et al., 2011), while the absorption promoters are oils.
  • Labrasol® and Gelucire® 50/13 have the particularity of having a high HLB of the order of 13-14 (Gattefossé) which allows their miscibility with water.
  • HLB the order of 13-14
  • the Labrasol® / water ratios are chosen in order to evaluate a possible impact of the Labrasol® concentration on the cells.
  • Gelucire® it is sought that the mixture remains in liquid form at room temperature, which limits the range of concentrations below 5%.
  • microemulsions composed of Miglyol® / Labrasol® provide three clear and visually stable compositions (Table 13).
  • composition 3 is retained because of various criteria.
  • the Tween® 80 used as a surfactant is known for its toxicity problems, the formula that contains the least seems safer.
  • the proportion of water is greater and therefore allows the introduction of more active ingredient.
  • the amount of Miglyol® important from the point of view of promoting absorption is also greater.
  • composition 1 is selected for cell assay.
  • baclofen The mechanism of passage of baclofen (Merino, et al., 1989) consists of an active passage through transporters but these are saturated in high doses. Not knowing the composition of Caco-2 cells in carriers, a high concentration of baclofen in the formulas is sought so that the carriers present are saturated. Thus, only the increase in paracellular passage will be evaluated.
  • the saturation concentration of baclofen in water is 3 mg / ml (internal preformulation ratio).
  • its solubility is strongly dependent on pH as the amine and carboxylic functions present on the molecule indicate.
  • fumaric acid at 0.01 M demonstrated to be compatible with baclofen by the internal preformulation ratio, makes it possible to double the solubility of baclofen at 6 mg / ml.
  • the pH is then 3.88.
  • the pH of a microemulsion does not influence its stability or its particle size if the surfactants used are not ionized or ionizable.
  • the replacement of the aqueous phase of the microemulsions with 0.01M fumaric acid at 6 mg / ml of baclofen does not cause visual destabilization of the microemulsions.
  • the stability of the systems is also monitored by particle size measurements at 14 and 45 days after the completion of the microemulsions.
  • Captex® / Capmul® emulsion a 21.3 nm measurement is obtained at 14 days for the placebo formula, which confirms the presence of a microemulsion.
  • a measurement at 24.2 nm is obtained for the formula with active principle indicating that the active ingredient does not influence the particle size as suggested by the study of (Prajapati, et al., 2012) .
  • studies by Buyukozturk et al (2010) and Gundogdu et al (2011) show an influence of the active ingredient on the size of the globules.
  • the measurement is 27.2 nm, which confirms the stability of the system. In order to study the influence of dilution on our sample, different dilutions were made.
  • the granulometry measurement of the Miglyol® / Labrasol® emulsion could not be performed because of the high viscosity of the medium measured at 423 cP.
  • the system is diluted with the understanding that the dilution does not affect the particle size of the emulsion, an effect supported by Prajapati et al.
  • the measurements with active at 14 days seem superior to those obtained on placebo.
  • the 45-day active measures are of the same order of magnitude as those of the placebo emulsion. It therefore seems difficult to conclude here on the particle size stability of the Captex® / Capmul® emulsion. We can still visually observe the absence of phase shift during the two months of observation, which allows us to conclude on the macroscopic stability of the systems.
  • the permeability values are very low, sometimes even lower than that of non-formulated baclofen.
  • baclofen concentrations deposited on cells for these tests are twice as high as that of the negative control. It may be thought that the concentration of the control is not quite at full saturation of the carriers.
  • the permeabilities can not be totally compared to each other since they depend on the concentration of active ingredient which is different from one formula to another.
  • the Gélucire® trials illustrate this point. In fact, Gelucire® concentration is higher for Gelucire® 5% than for Gelucire® 1%, even after dilution.
  • baclofen occurs only after a certain threshold of Labrasol® compared to the concentration of baclofen.
  • Neusilin® a silicate with a capacity of adsorption three times greater than that of microcrystalline cellulose
  • the adsorption technique is preferred because it allows the introduction of larger amounts of liquid relative to the granulation. Indeed, the latter technique also requires the adsorption of a certain amount of water which reduces the volume available for the oil.
  • a dry mixture containing 60% of Labrasol® is obtained which is encouraging and may allow the introduction of this powder into a pharmaceutical oral form.

Claims (10)

  1. Orale pharmazeutische Formulierung auf der Grundlage einer Mikroemulsion mit einer wässrigen Lösung, die zumindest einen BCS Wirkstoff (Biopharmaceutics Classification System = Biopharmazeutisches Klassifizierungssystem) der Klasse III umfasst, wobei der Wirkstoff Baclofen ist, und einer Ölphase, umfassend einen öligen Hilfsstoff, der bei Berührung mit Wasser selbstemulgierbar ist, wobei der bei Berührung mit Wasser selbstemulgierbare ölige Hilfsstoff eine Mischung aus Mono-, Di- und Triglyceriden und veresterten Fettsäuren PEG-8 in einer Menge von 50 bis 80 % Caprylsäure und 20 bis 50 % Caprinsäure ist.
  2. Formulierung nach Anspruch 1, wobei der bei Berührung mit Wasser selbstemulgierbare ölige Hilfsstoff einen HLB-Wert von mehr als 12 aufweist.
  3. Formulierung nach einem beliebigen der vorstehenden Ansprüche, wobei die ölige Phase 1 bis 50 % der Mikroemulsion, vorzugsweise 2 bis 30 %, besonders bevorzugt 5 bis 25 %, ausmacht.
  4. Formulierung nach einem beliebigen der vorstehenden Ansprüche, wobei die Mikroemulsion eine Ölin-Wasser-Mikroemulsion ist, die aus der wässrigen Phase und dem bei Berührung mit Wasser selbstemulgierbaren öligen Hilfsstoff besteht.
  5. Formulierung nach einem beliebigen der vorstehenden Ansprüche, wobei der bei Berührung mit Wasser selbstemulgierbare ölige Hilfsstoff in einem Verhältnis von 1:10 bis 1:100 Gew.-% im Verhältnis zum Wirkstoff vorhanden ist.
  6. Formulierung nach einem beliebigen der vorstehenden Ansprüche in flüssiger Form, umfassend die Mikroemulsion.
  7. Formulierung nach einem beliebigen der vorstehenden Ansprüche 1 bis 5 in fester Form.
  8. Formulierung nach Anspruch 7 in Form einer weichen oder starren Kapsel, die die Mikroemulsion im Kapselinnern umfasst.
  9. Formulierung nach Anspruch 7 in Tablettenform, die einen neutralen Träger umfasst, der mit der Mikroemulsion überzogen oder imprägniert, getrocknet und dann mit Presshilfsstoffen verpresst ist.
  10. Formulierung nach einem beliebigen der vorstehenden Ansprüche für ihre Verwendung bei der Behandlung von Alkoholabhängigkeit oder der Aufrechterhaltung des Alkoholentzugs.
EP13729029.2A 2012-06-14 2013-06-14 Orale pharmazeutische formulierung mit bcs-klasse iii-molekülen Active EP2861216B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1255593A FR2991879B1 (fr) 2012-06-14 2012-06-14 Formulation pharmaceutique orale de molecules bcs de classe iii
PCT/EP2013/062398 WO2013186370A1 (fr) 2012-06-14 2013-06-14 Formulation pharmaceutique orale de molecules bcs de classe iii

Publications (2)

Publication Number Publication Date
EP2861216A1 EP2861216A1 (de) 2015-04-22
EP2861216B1 true EP2861216B1 (de) 2019-04-17

Family

ID=48626457

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13729029.2A Active EP2861216B1 (de) 2012-06-14 2013-06-14 Orale pharmazeutische formulierung mit bcs-klasse iii-molekülen

Country Status (6)

Country Link
US (1) US10258692B2 (de)
EP (1) EP2861216B1 (de)
ES (1) ES2733222T3 (de)
FR (1) FR2991879B1 (de)
HK (1) HK1207963A1 (de)
WO (1) WO2013186370A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11324696B2 (en) 2016-09-09 2022-05-10 Azurity Pharmaceuticals, Inc. Suspensions and diluents for metronidazole and baclofen

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105572B2 (en) * 2000-02-04 2006-09-12 Takeda Pharmaceutical Company Limited Stable emulsion compositions
US20050090554A1 (en) * 2003-09-12 2005-04-28 John Devane Treatment of gastroparesis and nonulcer dyspepsia with GABAB agonists
EP1706098A4 (de) * 2003-11-26 2012-08-15 Supernus Pharmaceuticals Inc Mizellare systeme, die sich zum transport von lipophilen bzw. hydrophoben verbindungen eignen
EP1961412A1 (de) * 2006-12-27 2008-08-27 LEK Pharmaceuticals D.D. Selbstmikroemulgierende Arzneimittelabgabesysteme
US20100029771A1 (en) * 2008-07-31 2010-02-04 Olivier Ameisen Treatment of addictive disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11324696B2 (en) 2016-09-09 2022-05-10 Azurity Pharmaceuticals, Inc. Suspensions and diluents for metronidazole and baclofen
US11446246B2 (en) 2016-09-09 2022-09-20 Azurity Pharmaceuticals, Inc. Suspensions and diluents for metronidazole and baclofen

Also Published As

Publication number Publication date
FR2991879A1 (fr) 2013-12-20
WO2013186370A1 (fr) 2013-12-19
EP2861216A1 (de) 2015-04-22
FR2991879B1 (fr) 2014-11-21
HK1207963A1 (en) 2016-02-19
US10258692B2 (en) 2019-04-16
ES2733222T3 (es) 2019-11-28
US20150165032A1 (en) 2015-06-18

Similar Documents

Publication Publication Date Title
Parmar et al. Self nano-emulsifying drug delivery system for Embelin: Design, characterization and in-vitro studies
WO1996033697A1 (fr) Formulation auto-emulsionnable formant une emulsion huile dans l'eau
Goyal et al. Self microemulsifying drug delivery system: A method for enhancement of bioavailability
Eleftheriadis et al. Development and characterization of a self-nanoemulsifying drug delivery system comprised of rice bran oil for poorly soluble drugs
Obitte et al. Self-nanoemulsifying drug delivery systems based on melon oil and its admixture with a homolipid from Bos indicus for the delivery of indomethacin
Krishnamoorthy et al. Design, formulation, in vitro, in vivo, and pharmacokinetic evaluation of nisoldipine-loaded self-nanoemulsifying drug delivery system
Elnaggar et al. Self-emulsifying preconcentrates of daidzein–phospholipid complex: design, in vitro and in vivo appraisal
Baek et al. Oral absorption of a valsartan-loaded spray-dried emulsion based on hydroxypropylmethyl cellulose
Cheng et al. Preparation and in vitro/in vivo evaluation of puerarin solid self-microemulsifying drug delivery system by spherical crystallization technique
Pohlen et al. Preparation, physicochemical characterisation and DoE optimisation of a spray-dried dry emulsion platform for delivery of a poorly soluble drug, simvastatin
Sharma et al. Formulation and evaluation of self emulsifying drug delivery system of ibuprofen using castor oil
Liu et al. Solidified phospholipid-TPGS as an effective oral delivery system for improving the bioavailability of resveratrol
Gade et al. Formulation and evaluation of self-emulsifying orlistat tablet to enhance drug release and in vivo performance: factorial design approach
CA2747269C (fr) Formulation pharmaceutique de fenofibrate nanonise
EP3033110A1 (de) Neuartiges selbstemulgierendes instantfeststoffsystem aus cyclodextrinen und öl(en) zur oralen verabreichung
EP2861216B1 (de) Orale pharmazeutische formulierung mit bcs-klasse iii-molekülen
CN111093637A (zh) 药物组合物
Vasam et al. Formulation, characterization, and Taguchi design study of eplerenone lipid-based solid dispersions integrated with gelucire
KR102393620B1 (ko) 퀘세틴을 함유하는 나노에멀젼 조성물의 제조방법 및 이를 통해 제조된 퀘세틴을 함유하는 나노에멀젼 조성물
Kendre et al. Novel formulation strategy to enhance solubility of quercetin
WO2021078412A1 (fr) Formulations fractales
CN101711739B (zh) 卡马西平的口服药物组合物
EP2237769B1 (de) Selbstemulgierbare flüssige florfenicolzusammensetzung als zusatz für das trinkwasser von nutztieren
Singh et al. Tacrolimus loaded liquid and solid self-microemulsion preconcentrates: development and evaluation
Banerjee et al. Application of self nano emulsifying drug delivery system for clarithromycin

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150114

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1207963

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20180117

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/00 20060101ALI20190108BHEP

Ipc: A61K 47/14 20170101ALI20190108BHEP

Ipc: A61K 9/48 20060101ALI20190108BHEP

Ipc: A61K 9/107 20060101AFI20190108BHEP

Ipc: A61K 31/197 20060101ALI20190108BHEP

Ipc: A61K 9/16 20060101ALI20190108BHEP

Ipc: A61K 47/12 20060101ALI20190108BHEP

Ipc: A61K 47/10 20170101ALI20190108BHEP

Ipc: A61K 9/20 20060101ALI20190108BHEP

Ipc: A61K 9/50 20060101ALI20190108BHEP

INTG Intention to grant announced

Effective date: 20190205

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Free format text: NOT ENGLISH

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602013053999

Country of ref document: DE

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1120794

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190515

Ref country code: IE

Ref legal event code: FG4D

Free format text: LANGUAGE OF EP DOCUMENT: FRENCH

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20190417

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190417

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190817

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190417

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190417

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190417

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190717

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190417

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190417

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2733222

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20191128

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190417

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190417

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190417

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190718

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190717

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1120794

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190417

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190817

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602013053999

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190417

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190417

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190417

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190417

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190417

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190417

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190417

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190417

26N No opposition filed

Effective date: 20200120

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20190630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190417

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190614

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190630

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190614

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190630

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190630

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190417

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190417

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190417

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20130614

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190417

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230427

P02 Opt-out of the competence of the unified patent court (upc) changed

Effective date: 20230513

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20230523

Year of fee payment: 11

Ref country code: FR

Payment date: 20230523

Year of fee payment: 11

Ref country code: DE

Payment date: 20230523

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20230523

Year of fee payment: 11

Ref country code: ES

Payment date: 20230703

Year of fee payment: 11